日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials

结直肠癌患者在 I 期临床试验中的生存结果和预后模型

Kam, Audrey E; Pendurti, Gopichand; Shah, Umang H; Ghalib, Mohammad H; Chaudhary, Imran; Chuy, Jennifer; Rajdev, Lakshmi; Kaubisch, Andreas; Aparo, Santiago; Mantzaris, Ioannis; Goel, Sanjay

IL1RAP potentiates multiple oncogenic signaling pathways in AML

IL1RAP可增强急性髓系白血病中的多种致癌信号通路

Kelly Mitchell ,Laura Barreyro ,Tihomira I Todorova ,Samuel J Taylor ,Iléana Antony-Debré ,Swathi-Rao Narayanagari ,Luis A Carvajal ,Joana Leite ,Zubair Piperdi ,Gopichand Pendurti ,Ioannis Mantzaris ,Elisabeth Paietta ,Amit Verma ,Kira Gritsman ,Ulrich Steidl

Gluteal artery injuries including pseudoaneurysm associated with powered bone marrow biopsies

臀动脉损伤,包括与动力辅助骨髓活检相关的假性动脉瘤

Singh, Aditi P; Pendurti, Gopichand; Singh, Shashi; Shestopalov, Alexander; Pacello, Thomas; Reed, Louis J

PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome

PAK1 是急性髓系白血病和骨髓增生异常综合征的治疗靶点

Ashley Pandolfi, Robert F Stanley, Yiting Yu, Boris Bartholdy, Gopichand Pendurti, Kira Gritsman, Jacqueline Boultwood, Jonathan Chernoff, Amit Verma, Ulrich Steidl

Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1

癌症免疫疗法的新兴靶点:超越 CTLA-4 和 PD-1

Assal, Amer; Kaner, Justin; Pendurti, Gopichand; Zang, Xingxing

Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment

靶向PI3K/AKT/mTOR通路:肺癌治疗的潜力

Cheng, Haiying; Shcherba, Marina; Pendurti, Gopichand; Liang, Yuanxin; Piperdi, Bilal; Perez-Soler, Roman

Formation of three-dimensional hydrogel multilayers using enzyme-mediated redox chain initiation

利用酶介导的氧化还原链引发反应形成三维水凝胶多层结构

Johnson, Leah M; Deforest, Cole A; Pendurti, Aishwarya; Anseth, Kristi S; Bowman, Christopher N